WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Flow Cytometry in the 21st Century: A Comprehensive Review of Advances, Applications and Challenges

Narendra Malluri [1], Prof. Dr. A. Krishanmanjari Pawar [2*]

[1]Student, Department of Pharmaceutical Analysis, A.U. College of Pharmaceutical Sciences, Andhra university, Visakhapatnam - 530003
[2]Professor and HoD of Department of Pharmaceutical Analysis, A.U. College of Pharmaceutical Sciences, Andhra university, Visakhapatnam - 530003
[2] Cor Email- akmpawar@andhrauniversity.edu.in*

A B S T R A C T

Flow cytometry has revolutionized the study of individual cells, offering a fast and detailed method for assessing various cell properties. This review discusses the advancements, applications, challenges and future directions of flow cytometry from 2000 to 2025. Recent inventions comparable to high-output systems, multicolor immunophenotypic and automated data analysis have significantly broadened their use in fields such as immunology, oncology, infectious disease study and experimental medicine. In clinical settings, flow cytometry plays a vital role in diagnosing conditions, forecasting issues, and tracking patient progress. It is also the foundation of translational exploration, helping to bridge the gap between laboratory discoveries and new treatments. However, proteomics still faces hurdles, including complex data interpretation, the need for standardized protocols, and limited access to advanced equipment. Emerging technologies, such as small-flyspeck flow cytometry and multiplex assays, are addressing these issues while unleashing new exploration possibilities. Looking ahead, the integration of artificial intelligence and machine learning into flow cytometry is expected to enhance both precision and accuracy. By linking this to clinical practice, flow cytometry remains a driving force behind personalized drug development, which will eventually improve patient care. This review underscores the growing significance of flow cytometry in biomedical research, highlighting the need for ongoing innovation to overcome current challenges and fully realize its potential.

Keywords: Flow cytometry, florescence analysis, single cell analysis, cell sorting, artificial intelligence, machine learning and automated data analysis.

1. Introduction

Flow cytometry is a potent logical fashion that has converted how scientists estimate both cellular and sub-cellular features across different natural systems. At its core, the technology enables quick, high-throughput examination of individual cells suspended in fluid, furnishing quantitative and qualitative data on physical and chemical characteristics with remarkable perfection. Since its development, flow cytometry has evolved into a multidimensional platform suitable for assaying complex cell populations using luminescence labeled antibodies and other molecular examinations.[1,2]

This technology operates on principles of fluidics, optics, and electronics, allowing simultaneous dimension of multiple cellular parameters similar as cell size, granularity, viability and protein expression in real time.[3] Modern advancements have expanded its capacity to measure dozens of labels at formerly, through inventions like spectral flow cytometry and the integration of artificial intelligence tools for big data analysis.[4,5]

The impact of flow cytometry across a variety of disciplines, including immunology, oncology, hematology, stem cell disquisition and contagious conditions. In immunological studies, it plays a critical part in relating vulnerable cell subsets, characterizing activation countries, and tracking vulnerable responses during infection or vaccination.[6,7] In cancer biology, it's considerably used for immunophenotypic excrescences, detecting rare nasty cells, and assessing excrescence diversity.[8] Likewise, flow cytometry has come an invaluable clinical tool, supporting diagnostics, prognostics, and remedial monitoring. Its clinical connection is instanced by its operation in detecting minimal residual complaint in leukemia cases, assessing graft harmony in transplant medicine, and covering vulnerable reconstitution in HIV/ AIDS.[1,3]

As the field advances, the integration of flow cytometry with genomic, proteomic, and computational tools promises to unleash indeed deeper perceptivity into cellular complexity. With its expanding capabilities and operations, flow cytometry stands as a necessary pillar in ultramodern biomedical exploration and diagnostics.

1.1 Definition of Flow Cytometry

Flow cytometry is a lase based analytical technology used to measure the physical and chemical properties of cells or particles in a fluid suspense. By passing cells through a focused ray ray one at a time, the system able to detects scattered light and luminescence signals emitted by fluorescently labeled labels on or within the cells. These signals are reused to dissect parameters such as cell size, granularity, and molecular expression, enabling rapid analysis

of thousands of cells per second.[1,4] Advanced ways like fluorescence- actuated cell sorting(FACS) allow for the separation of specific cell populations for downstream applications.[2,3]

1.2. Historical background and evolution

The origins of flow cytometry can be traced back to the 1950s when Wallace Coulter developed the Coulter principle for counting particles in suspension.[2,4] The first fluorescence-based flow cytometers emerged in the 1960s and the 1970s, incorporating spotlights and photodetectors to measure fluorescence intensity.[4,8] Over the past three decades, flow cytometry has experienced significant advancements, including the introduction of multicolor flow cytometry, which allows the contemporaneous analysis of multiple cellular labels using distinct fluorophores. [9-11] Recent inventions have focused on miniaturization, robotization, and integration with machine learning algorithms to enhance data analysis and interpretation.[12-15]

1.3. Importance of Flow Cytometry in Various Fields

Flow cytometry is necessary in numerous scientific and clinical disciplines because of its versatility and precision.

- **Immunology:** It is extensively used to study immune cell populations, cytokine production, and immune responses during infections or autoimmune disorders. [1,6,16]
- **Oncology:** Flow cytometry aids in cancer diagnosis, prognosis, and monitoring by identifying tumor-specific antigens and analyzing tumor microenvironments .[4,8,16]
- **Infectious diseases:** It helps to identify pathogens, measure immune responses, and evaluate vaccine efficacy. [1,17,4]
- **Hematology:** Flow cytometry is critical for diagnosing hematological malignancies, such as leukemia, by analyzing cell surface markers. [8,16,17]
- **Stem cell research:** It enables the characterization and sorting of stem cells based on their unique markers for regenerative medicine applications. [18,19]

By bridging basic research with clinical practice, flow cytometry has significantly advanced our understanding of cellular processes, driving innovations in diagnostics and therapeutics.

2. Technological advancements in flow cytometry

2.1 Spectral Flow Cytometry: Advances and Applications

Spectral flow cytometry has revolutionized the field by enabling the simultaneous detection of a broader range of fluorochromes, overcoming the limitations of spectral overlap inherent in conventional flow cytometry. Unlike traditional systems that rely on discrete bandpass filters, spectral flow cytometers capture the entire emission spectrum of fluorochromes using prisms and multiple detectors. [4,10] This approach allows for more parameters to be analyzed per cell, with some instruments now capable of detecting up to 40 or more markers simultaneously. [4,20] These advancements have significantly enhanced high-dimensional data analysis, particularly in immunophenotyping and tumor microenvironment studies. [21,22]

In addition, spectral flow cytometry has improved sensitivity and reduced compensation requirements, making it more suitable for complex experiments. The ability to resolve closely overlapping fluorescence spectra has expanded its applications in fields such as oncology, where accurate marker detection is essential for identifying rare cancer cell populations. [22,23]

2.2 Mass Cytometry: Capabilities and Limitations

Mass cytometry, or cytometry by time-of-flight (CyToF), has emerged as a revolutionary technique during this period, replacing fluorochromes with isotopes as cell markers. This invention eliminates spectral overlap entirely and allows for the simultaneous measurement of over 50 parameters per cell. Mass cytometry is particularly useful for studying intricate natural systems, such as the immune system, where high-dimensional data are essential. [4,20]

While mass cytometry offers unparalleled multiplexing capabilities, it also presents challenges, such as high costs, slower sample processing rates compared to fluorescence-based systems, and the need for technical equipment. Despite these limitations, it has become an important tool in systems biology and multi-omics research. [10,24,15]

2.3 Development of Novel Fluorochromes and Reagents

The development of new fluorochromes and tandem dyes has significantly expanded the range of parameters in flow cytometry experiments. These reagents exhibit better stability, reduced spectral interference, and higher yields, enabling more precise analyses. [25] Advances in polymer dyes and fluorescent proteins have further enhanced multicolor experiments by adding brilliance while minimizing signal interference.

In addition to fluorochromes, the use of fluorescent microspheres and droplet microfluidics has enabled researchers to dissect intracellular targets, such as cytokines and enzymes, with greater precision. [26] These inventions have broadened the scope of flow cytometry operations in both basic research and clinical diagnostics. [24,27,28,29]

2.4 Integration with Genomics and Proteomics

The integration of flow cytometry with other omics technologies has opened new avenues for understanding cellular dynamics in complex or previously uncharacterized conditions. For example:

- **Genomics:** Single-cell RNA sequencing combined with flow cytometry enables researchers to link gene expression profiles to phenotypic characteristics. [7,24]
- **Proteomics:** The use of mass spectrometry-based proteomics alongside flow cytometry provides insight into protein expression and post-translational modifications at the single-cell level. [20,30]

In addition, imaging flow cytometry has emerged as a hybrid technology that combines traditional flow cytometry with high-resolution imaging. This integration allows for the simultaneous analysis of cellular morphology and molecular markers, making it particularly useful for studying rare events, such as circulating tumor cells or apoptotic processes. [3,4,6,14]

3.Applications of Flow Cytometry

3.1 Immunology: Immune Cell Profiling and Diagnostics

Part in assaying immune cell populations and functions

Flow cytometry is necessary in immunology, enabling the detailed analysis of vulnerable cell subsets, activation states, and cytokine products. It is extensively used to identify t-, b-, and natural killer (NK) cell populations, as well as to study their functional responses in health and disease. For example, spectral flow cytometry has enhanced the resolution of vulnerable cell phenotyping by allowing contemporaneous analysis of over 40 labels per cell, perfecting the identification of rare vulnerable subsets similar to nonsupervisory or exhausted T cells. [4,31]

Case studies and recent findings

Recent studies have demonstrated the utility of flow cytometry in diagnosing primary immunodeficiency conditions (PIDs) with vulnerable dysregulation. [4] For example, phospho-flow cytometry has been used to describe aberrant JAK-STAT signaling in cases of autoimmune diseases caused by JAK1 gain-of-function mutations. [32,33] Full-diapason flow cytometry (FSFC) has also been applied to cover vulnerable responses in COVID-19 cases, relating specific monocyte and lymphocyte subsets associated with disease severity.[31]

3.2 Oncology: Cancer Diagnosis and Monitoring

Operations in cancer opinion and monitoring

Flow cytometry is a foundational technology in oncology for diagnosing hematological malignancies, covering minimum residual disease (MRD), and characterizing excrescence microenvironments. It enables the identification of cancer-specific biomarkers and vulnerable autographs that guide remedial decisions. [24,27] For illustration, FSFC has been used to study infiltrating lymphocytes and their role in cancer progression and response to immunotherapy. [24]

Impact on personalized medicine

The integration of flow cytometry into cancer immunotherapy exploration has advanced individualized drug therapy by identifying predictive biomarkers for treatment response. For example, CD38 expression on macrophages was validated as a biomarker for hepatocellular melanoma cases entering anti-PD-1 remedy using FSFC. Cytometric assays have also been employed to estimate vulnerable checkpoint inhibitors, similar to asanti-ctla-4 antibodies, by assaying T-cell reduction and activation in tumours. [24,27]

3.3 Microbiology: Pathogen and Microbial Analysis

Ways for detecting and assaying microorganisms

Flow cytometry is extensively used in microbiology to detect and dissect microorganisms, such as bacteria, contagions, and fungi. Methods such as fluorescence labeling and viability staining enable rapid assessment of microbial populations based on size, granularity, and metabolic activity. These styles are particularly useful for studying microbial pathogenesis and host-pathogen relationships. [6,34]

Advances in pathogen detection

Recent advances include the use of flow cytometry for high-throughput pathogen discovery in clinical samples. For example, multiplex assays combining flow cytometry with fluorescent examinations have improved the detection of co-infections or antibiotic-resistant strains. [6,34] In addition, FSFC has been applied to study host vulnerable responses during infections like COVID-19 by characterizing pathogen-specific memory B and T cells. [35]

3.4 Drug Development: High-Throughput Screening

High-throughput screening for drug discovery on cells

Flow cytometry plays a critical role in medicine discovery by enabling high-throughput screening of medicine goods on cellular phenotypes. It allows experimenters to assess drug-induced changes in cell viability, apoptosis, proliferation, and intracellular signaling pathways. For example, flow cytometric assays have been used to estimate the efficacy of anti-cancer medicines by measuring cell death or vulnerable activation. [36-38]

Exemplifications of successful operations

In translational exploration, flow cytometry has been employed to screen monoclonal antibodies targeting vulnerable checkpoints, such as PD-1/PD-L1 or CTLA-4, for cancer immunotherapy. Another successful operation includes its use in testing small patch impediments for autoimmune conditions by assaying cytokine products or T-cell activation profile.[39]

3.5 Plant Biology: Applications in Plant Science

Assessing factory cell viability and pathogen detection

Flow cytometry has been extended to biology by enabling the assessment of factory cell viability under stress conditions or during pathogen infection. Fluorescent colorings are used to measure parameters similar to membrane integrity, reactive oxygen species (ROS) products, or DNA content in factory cells. [24]

4. Challenges in flow cytometry

4.1 Technical Limitations

Despite its versatility, flow cytometry faces several specialized challenges.

Resolution and perceptivity: Issues similar to spectral imbrication between fluorochromes and limitations in detecting dim signals or rare populations are common. Although advancements such as spectral flow cytometry have improved resolution, achieving high perceptivity across multiple parameters remains challenging due to instrument noise and variability in fluorochrome brightness. [4,10]

Data interpretation: Multicolor trials frequently compensate for spectral spillover, which can introduce errors if not performed directly. In addition, the complexity of gating strategies for relating specific cell populations can lead to inconsistent results across laboratories. [10,20]

Cell damage: The process of dividing cells from apkins or pulpits for analysis can alter protein expression or damage cells, affecting post-analysis viability and downstream applications. [4,2]

4.2 Cost and Accessibility

The high cost of flow cytometers and reagents poses significant challenges.

Profitable walls: Advanced instruments, such as spectral or mass cytometers, are precious to buy and maintain, limiting their availability to well-funded exploration institutions and clinical laboratories. [40,41]

The cost of fluorochrome-conjugated antibodies and other reagents adds to the fiscal burden, particularly for multicolor trials using numerous markers. [8,40]

In resource-limited settings in low-income regions, the lack of affordable instruments and a trained labor force restricts the use of flow cytometry in routine diagnostics and exploration applications. [40,42]

4.3 Data complexity and analysis

The addition of complexity to flow cytometry datasets presents significant logical challenges

Large datasets: High-dimensional data generated by ultramodern instruments require advanced computational tools for analysis. Homemade gating is laborious and prone to driver bias, especially when assaying rare populations or complex phenotypes. [20,24]

Bioinformatics: Integration of flow cytometry data with other omics datasets (e.g., genomics and proteomics) requires sophisticated bioinformatics channels that are not readily available in all laboratories. [24,43]

Automated analysis: Although machine learning algorithms show promise in automating data analysis, their implementation is hindered by a lack of standardized work and user-friendly software interfaces. [43,44]

4.4 Standardization and Reproducibility

Thickness in flow cytometry trials is a patient issue.

Lack of guidelines: Despite efforts to establish stylish practices (e.g., micyt norms), adherence to standardized protocols remains inconsistent, particularly in non-specialized labs.

Protocol variability: Differences in sample medication, instrument settings, and reagent quality across laboratories can lead to variability in results, making it difficult to compare findings.

Reproducibility issues: Variability in reagent performance (e.g., lot-to-lot differences in fluorochrome-conjugated antibodies) further complicates reproducibility, highlighting the need for strict quality control measures and robust substantiation protocols. [4,45,46]

5. Unborn trends and directions

5.1 Emerging technologies

Prognostications on next-generation flow cytometry inventions

Spectral flow cytometry: The field is anticipated to see further advancements in spectral flow cytometry, with instruments capable of assaying up to 100 parameters contemporaneously. This will enhance the resolution of cellular phenotyping and enable deeper insights into complex natural systems. [10]

Mass cytometry expansion: Inventions in cytof (mass cytometry) are anticipated to ameliorate throughput and reduce costs, making it more accessible for high-dimensional single-cell analysis in clinical and exploration settings. [8]

Integration with microfluidics: Emerging technologies such as drop microfluidics and conflation systems are expected to expand the operations of flow cytometry, particularly for studying buried molecules such as cytokines and enzymes. [6]

Hybrid systems: Development of mongrel systems combining flow cytometry with imaging or other discovery styles (e.g., Raman spectroscopy) will allow contemporaneous morphological and molecular analysis, broadening its mileage in different fields. [34]

5.2 Expanding operations: Implicit new fields and areas of study

Multi-omics integration: Flow cytometry is anticipated to play a vital part in multi-omics studies by integrating with genomics, transcriptomics and proteomics to give comprehensive insight into cellular functions. [47]

Food safety: It is expected that developments in microbial flow cytometry would improve food safety monitoring by facilitating the quick identification of foodborne bacteria and the evaluation of antibiotic resistance. [34,48]

5.3 Sustainability and eco-friendly practices

Trends towards reducing waste and perfecting environmental impact

Reagent optimization: Sweats are being made to develop eco-friendly reagents that reduce chemical waste while maintaining high sensitivity and particularity.

Green protocols: Laboratories are decreasingly espousing sustainable practices, such as recovering consumables and using digital data storehouse rather than published records, to align with global sustainability goals.

These unborn trends punctuate the eventuality for flow cytometry to continue evolving as a protean tool for biomedical exploration while addressing current limitations through technological invention, expanded operations, AI integration, and eco-conscious practices.[27,35,48,6]

6. Recent Advances and Future Directions

6.1 Overview of the main conclusions

From 2010 to 2025, this review emphasizes the revolutionary role that flow cytometry had in clinical practice and biomedical research. The creation of new fluorochromes, spectral and mass cytometry, and the combination of flow cytometry with omics technologies are important developments. Operations gauge immunology, oncology, microbiology, medicine development, and factory biology, with significant benefactions to fields like cancer immunotherapy, pathogen discovery, and substantiated drug. Despite its versatility, challenges similar as specialized limitations, high costs, data

complexity, and reproducibility issues persist. Unborn trends point toward AI-driven data analysis, eco-friendly practices, and expanded operations in arising fields. [4,49,50,51]

6.2 Aritical analysis of current exploration

Strengths:

- The reviewed studies demonstrate the versatility of flow cytometry in both exploration and clinical settings. For illustration, its capability to perform high-dimensional single-cell analysis has been vital in relating rare cell populations in immunology and oncology.
- Technological advancements like spectral flow cytometry have significantly bettered resolution and perceptivity, enabling deeper perceptivity into cellular heterogeneity.

The integration of flow cytometry with omics technologies has opened new avenues for multidimensional natural studies.

Limitations:

- Numerous studies punctuate the specialized challenges associated with spectral imbrication and compensation in multicolor experiments.
- The high cost of advanced instruments and reagents limits availability in resource-constrained settings.
- Data complexity remains a significant chain; while machine literacy tools are promising, their relinquishment is still limited due to a lack of standardization and stoner-friendly interfaces.
- Reproducibility issues stemming from protocol variability across laboratories undermine the trustability of results.[4,52,53]

6.3 Counter accusations for research and clinical practice

How advancements can influence healthcare and scientific research

- **Research:** The capability to dissect multiple parameters contemporaneously has accelerated discoveries in immunology, oncology, and microbiology. For illustration, flow cytometry's part in relating vulnerable cell subsets has strengthened our understanding of vulnerable responses during infections like Covid-19.
- **Clinical practice:** Flow cytometry has become necessary for diagnosing hematological malignancies and monitoring minimal residual disease (MRD). It also supports individualized medicine by identifying predictive biomarkers for therapeutic response.
- **Drug development:** High-throughput screening capabilities have streamlined medicine discovery processes by enabling rapid evaluation of medicine goods on cellular phenotypes.
- **Unborn implicit:** Arising technologies like imaging flow cytometry are anticipated to enhance diagnostic delicacy by combining morphological and molecular analyses. [4,24,27]

6.4 Gaps in current knowledge and unborn exploration directions

Identification of areas demanding farther disquisition and specialized advancements

Enhanced fluorochromes with reduced spectral imbrication are demanded to ameliorate multicolor trials. [54] Development of affordable instruments for resource-limited settings should be prioritized to homogenize access to flow cytometry technology. [1] In Data analysis there's a need for standardized machine learning fabrics that can handle large datasets while icing reproducibility across studies. [24,55,56]

Integration with bioinformatics channels for multi-omics studies remains underexplored. [24] Operations in neuroscience (e.g., assaying neural stem cells) and environmental monitoring (e.g., microbial diversity) bear farther disquisition. [57,58] The use of flow cytometry in factory biology remains underutilized compared to its eventuality. [24]

Exploration into eco-friendly reagents and energy-efficient instruments is necessary to reduce the environmental impact on flow cytometry trials. [3,24]

By addressing these gaps through continued invention and collaboration between experimenters, clinicians, and assiduity stakeholders, flow cytometry can further solidify its part as a foundation technology in advancing healthcare and scientific discovery. [1,4,20]

The evolution of flow cytometry into a pivotal tool for single-cell analysis was propelled by the fusion of pharmaceutical innovations, engineering prowess, and biological discoveries, marking its inception in the mid-20th century.

7. Conclusion

Flow cytometry has endured remarkable advancements from 2010 to 2025, solidifying its position as a foundation technology in biomedical disquisition and clinical practice. Inventions analogous as spectral flow cytometry, mass cytometry, and new fluorochromes have significantly enhanced the resolution, perceptivity, and multiplexing capabilities of this fashion.

These advancements have expanded its operations across different fields, including immunology, oncology, microbiology, medicine development and factory biology. Flow cytometry has been necessary in diagnosing conditions, covering remedial responses, and advancing individualized drug. Still, challenges similar as specialized limitations, high costs, data complexity, and reproducibility issues remain patient walls to its broader relinquishment.

The future of flow cytometry is poised for farther metamorphosis with arising trends similar as the integration of artificial intelligence for automated data analysis,eco-friendly practices to reduce environmental impact, and the development of mongrel technologies combining flow cytometry with imaging or omics approaches. These inventions won't only address current challenges but also open new borders in exploration and diagnostics.

Continued invention and exploration are essential to enhance the capabilities and availability of flow cytometry. Experimenters and interpreters must unite to develop affordable instruments, formalized protocols, and robust logical tools. By addressing these challenges and using arising trends, the full eventuality of flow cytometry can be realized to drive improvements in understanding cellular dynamics, disease mechanisms, and remedial interventions.

This review underscores the significance of flow cytometry as a protean and necessary tool in advancing wisdom and healthcare. It calls upon the scientific community to embrace invention while addressing being walls to insure that this technology continues to evolve and profit different disciplines encyclopedically.

References

Betters DM. Use of flow cytometry in clinical practice. *J Adv Pract Oncol*. 2015;6(5):435–440. doi:10.6004/jadpro.2015.6.5.4

Virgo PF, Gibbs GJ. Flow cytometry in clinical pathology. *Ann Clin Biochem*. 2012;49(1):17–28. doi:10.1258/acb.2011.011128

Picot, J., Guerin, C.L., Le Van Kim, C. et al. Flow cytometry: retrospective, fundamentals and recent instrumentation. Cytotechnology 64, 109–130 (2012). https://doi.org/10.1007/s10616-011-9415-0

Robinson, J. P. (2022). Flow Cytometry: Past and Future. *BioTechniques*, *72*(4), 159–169. https://doi.org/10.2144/btn-2022-0005

Xiao Z, Darwish GH, Susumu K, Medintz IL, Algar WR. Prototype smartphone-based device for flow cytometry with immunolabeling via supra-nanoparticle assemblies of quantum dots. ACS Meas Sci Au. 2022;2:57-66.

O'Donnell EA, Ernst DN, Hingorani R. Multiparameter Flow Cytometry: Advances in High Resolution Analysis. Immune Netw. 2013 Apr;13(2):43-54. https://doi.org/10.4110/in.2013.13.2.43

Siddiqui, S., Livák, F. (2023). Principles of Advanced Flow Cytometry: A Practical Guide. In: Bosselut, R., Vacchio, M.S. (eds) T-Cell Development. Methods in Molecular Biology, vol 2580. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2740-2_5

Drescher H, Weiskirchen S, Weiskirchen R. Flow Cytometry: A Blessing and a Curse. *Biomedicines*. 2021 Nov 4;9(11):1613. doi:10.3390/biomedicines9111613

Chattopadhyay PK, Hogerkorp CM, Roederer M. A chromatic explosion: the development and future of multiparameter flow cytometry. *Immunology*. 2008 Dec;125(4):441–449. doi:10.1111/j.1365-2567.2008.02989.x7/978-1-0716-2740-2_5

Chattopadhyay PK, Roederer M. Cytometry: today's technology and tomorrow’s horizons. *Methods*. 2012 Feb;57(3):251–258. doi:10.1016/j.ymeth.2012.02.009

Maecker HT. Future Cytometric Technologies and Applications. In: Detrick B, Schmitz JL, Hamilton RG, editors. *Manual of Molecular and Clinical Laboratory Immunology*. Washington, DC: ASM Press; 2016. Chapter 25. doi:10.1128/9781555818722.ch25

Jiang J, Li X, Mao F, Wu X, Chen Y. Small molecular fluorescence dyes for immuno cell analysis. *Anal Biochem*. 2021;614:114063. doi:10.1016/j.ab.2020.114063

Sun J, Kroeger JL, Markowitz J. Introduction to multiparametric flow cytometry and analysis of high-dimensional data. In: Markowitz J, editor. *Translational Bioinformatics for Therapeutic Development*. Methods Mol Biol. 2021;2194:239–250. New York, NY: Humana. doi:10.1007/978-1-0716-0849-4_13

Liu Y, Zhao H, Fu B, Zhang N, Liu H, Li X, et al. Mapping cell phenomics with multiparametric flow cytometry assays. *Phenomics*. 2022;2(3):272–281. doi:10.1007/s43657-021-00031-0

Robinson JP, Ostafe R, Iyengar SN, Rajwa B, Fischer R. Flow cytometry: the next revolution. *Cells*. 2023 Jul 17;12(14):1875. doi: 10.3390/cells12141875.

Tárnok A, editor. Cytometry in stem cell research and therapy. *Cytometry A*. 2013;83A(1):1–4. doi: 10.1002/cyto.a.22243.

Nery AA, Nascimento IC, Glaser T, Bassaneze V, Krieger JE, Ulrich H. Human mesenchymal stem cells: From immunophenotyping by flow cytometry to clinical applications. *Cytometry A*. 2012 Oct 1;81(10):879-894. doi: 10.1002/cyto.a.22205.

Meyfour A, Pahlavan S, Mirzaei M, et al. The quest of cell surface markers for stem cell therapy. *Cell Mol Life Sci*. 2021;78(2):469-495. doi: 10.1007/s00018-020-03602-y.

Kyryk VM. Phenotyping and sorting of murine bone marrow haematopoietic stem cells using flow cytometry. *Biotechnologia Acta*. 2014;7(6):51–56. doi:10.15407/biotech7.06.051

McKinnon KM. Flow cytometry: An overview. *Curr Protoc Immunol*. 2018 Feb 21;120:5.1.1–5.1.11. doi: 10.1002/cpim.40.

Bhaumik S, Boyer J, Banerjee C, Clark S, Sebastiao N, Vela E, Towne P. Fluorescent multiplexing of 3D spheroids: Analysis of biomarkers using automated immunohistochemistry staining platform and multispectral imaging. *J Cell Biochem*. 2020 Dec;121(12):4974–4990. doi:10.1002/jcb.29827.

Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. *Cancer Discov*. 2015 Feb;5(2):118–123. doi:10.1158/2159-8290.CD-14-1118.

Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treat Rev*. 2020 Jun;86:102019. doi:10.1016/j.ctrv.2020.102019

Kala PS, Zubair M. Flow Cytometry Blood Cell Identification [Updated 2024 Sep 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Available from: https://www.ncbi.nlm.nih.gov/books/NBK608011/

Li M, Liu H, Zhuang S, Goda K. Droplet flow cytometry for single-cell analysis. *RSC Adv*. 2021;11(34):20944–20960. doi:10.1039/D1RA02636D.

Yang X, Liu W, Chan DC-H, Ahmed SU, Wang H, Wang Z, Nemr CR, Kelley SO. Fluorescent droplet cytometry for on-cell phenotype tracking. *J Am Chem Soc*. 2020 Sep 2;142(35):14805-14809. doi:10.1021/jacs.0c05276.

Chaudhary R, Das SS. Application of flow cytometry in transfusion medicine: The Sanjay Gandhi Post Graduate Institute of Medical Sciences, India experience. *Asian J Transfus Sci*. 2022 Jul–Dec;16(2):159–166. doi:10.4103/ajts.ajts_61_22. Available from: https://journals.lww.com/ajts/fulltext/2022/16020/application_of_flow_cytometry_in_transfusion.1.aspx

Pärnamets K, Pardy T, Koel A, Rang T, Scheler O, Le Moullec Y, Afrin F. Optical detection methods for high-throughput fluorescent droplet microflow cytometry. *Micromachines*. 2021 Mar 3;12(3):345. doi:10.3390/mi12030345.

Salomon R, Razavi Bazaz S, Li W, Gallego-Ortega D, Jin D, Ebrahimi Warkiani M. A method for rapid, quantitative evaluation of particle sorting in microfluidics using basic cytometry equipment. *Micromachines*. 2023 Mar 29;14(4):751. doi:10.3390/mi14040751.

Dimitriadis S, Dova L, Kotsianidis I, Hatzimichael E, Kapsali E, Markopoulos GS. Imaging flow cytometry: Development, present applications, and future challenges. *Methods Protoc*. 2024 Mar 23;7(2):28. doi:10.3390/mps7020028. Available from: https://www.mdpi.com/2409-9279/7/2/28

Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. *Eur Heart J*. 2021 Nov 7;42(42):4389–4400. doi:10.1093/eurheartj/ehab447.

Rawat A, Arora K, Shandilya J, Vignesh P, Suri D, Kaur G, Rikhi R, Joshi V, Das J, Mathew B, Singh S. Flow cytometry for diagnosis of primary immune deficiencies—A tertiary center experience from North India. *Front Immunol*. 2019;10:2111. doi:10.3389/fimmu.2019.02111.

O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. *N Engl J Med*. 2013 Jan 24;368(2):161–70. doi:10.1056/NEJMra1202117.

Payés C, Rodríguez JA, Friend S, Helguera G. Cell interaction analysis by imaging flow cytometry. In: Chen X, Wang J, editors. *Flow Cytometry—Recent Perspectives*. London: IntechOpen; 2013. Chapter 12. Available from: http://dx.doi.org/10.5772/51147

Lazarski CA, Hanley PJ. Review of flow cytometry as a tool for cell and gene therapy. *Cytotherapy*. 2024 Feb;26(2):103–112. doi:10.1016/j.jcyt.2023.10.005.

Joslin J, Gilligan J, Anderson P, Garcia C, Sharif O, Hampton J, Cohen S, King M, Zhou B, Jiang S, Trussell C, Dunn R, Fathman JW, Snead JL, Boitano AE, Nguyen T, Conner M, Cooke M, Harris J, Ainscow E, Zhou Y, Shaw C, Sipes D, Mainquist J, Lesley S. A fully automated high-throughput flow cytometry screening system enabling phenotypic drug discovery. *SLAS Discov*. 2018 Aug;23(7):697-707. doi:10.1177/2472555218773086. Epub 2018 May 29. PMID: 29843542; PMCID: PMC6055113.

Ding M, Baker D. Recent advances in high-throughput flow cytometry for drug discovery. *Expert Opin Drug Discov*. 2021 Mar;16(3):303-317. doi:10.1080/17460441.2021.1826433. Epub 2020 Oct 15. PMID: 33054417.

Edwards BS, Sklar LA. Flow cytometry: impact on early drug discovery. *J Biomol Screen*. 2015 Jul;20(6):689-707. doi:10.1177/1087057115578273. Epub 2015 Mar 24. PMID: 25805180; PMCID: PMC4606936.

Jeong S, Lee N, Park M-J, Jeon K, Song W. Currently used laboratory methodologies for assays detecting PD-1, PD-L1, PD-L2, and soluble PD-L1 in patients with metastatic breast cancer. *Cancers*. 2021 Oct 18;13(20):5225. doi:10.3390/cancers13205225. Available from: https://www.mdpi.com/2072-6694/13/20/5225

Baranovskii DS, Klabukov ID, Arguchinskaya NV, Yakimova AO, Kisel AA, Yatsenko EM, Ivanov SA, Shegay PV, Kaprin AD. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. *Stem Cell Investig*. 2022 Nov 8;9:7. doi:10.21037/sci-2022-025. PMID: 36393919; PMCID: PMC9659480.

Leith CP. Cost-effective flow cytometry testing strategies. *Clin Lab Med*. 2017 Dec;37(4):915–929. doi:10.1016/j.cll.2017.07.012.

Cao H, Oghenemaro EF, Latypova A, Abosaoda MK, Zaman GS, Devi A. Advancing clinical biochemistry: addressing gaps and driving future innovations. *Front Med (Lausanne)*. 2025 Apr 8;12:1521126. doi:10.3389/fmed.2025.1521126.

Carbonell P, Radivojevic T, García Martín H. Opportunities at the Intersection of Synthetic Biology, Machine Learning, and Automation. *ACS Synth Biol*. 2019 Jul 19;8(7):1474–7. doi:10.1021/acssynbio.8b00540.

Helleckes LM, Hemmerich J, Wiechert W, von Lieres E, Grünberger A. Machine learning in bioprocess development: from promise to practice. *Trends Biotechnol*. 2023 Jun;41(6):817–35. doi:10.1016/j.tibtech.2022.10.010. Epub 2022 Nov 28.

Luo Y, Pehrsson M, Langholm L, Karsdal M, Bay-Jensen A-C, Sun S. Lot-to-Lot variance in immunoassays—Causes, consequences, and solutions. *Diagnostics*. 2023 May 24;13(11):1835. doi:10.3390/diagnostics13111835.

Loh T, Sandberg S, Horvath A. Lot-to-lot reagent verification: challenges and possible solutions. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2022;60(5): 675-680. https://doi.org/10.1515/cclm-2022-0092

Zielinski JM, Luke JJ, Guglietta S, Krieg C. High throughput multi-omics approaches for clinical trial evaluation and drug discovery. *Front Immunol*. 2021 Mar 31;12:590742. doi:10.3389/fimmu.2021.590742.

Marutescu LG. Current and future flow cytometry applications contributing to antimicrobial resistance control. *Microorganisms*. 2023 May 16;11(5):1300. doi:10.3390/microorganisms11051300.

Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. *J Pharm Anal*. 2025 Mar 3;15:101248. doi:10.1016/j.jpha.2025.101248.

Kolluri S, Lin J, Liu R, et al. Machine learning and artificial intelligence in pharmaceutical research and development: a review. *AAPS J*. 2022;24(1):19. doi:10.1208/s12248-021-00644-3.

Zhang L, Lin J, Han Y, Zhang X, Liu R, Yang X, Wang Y, Yang Y, Yi X. Safety and efficacy evaluation of halicin as an effective drug for inhibiting intestinal infections. *Front Pharmacol*. 2024;15:1389293. doi:10.3389/fphar.2024.1389293.

Albertoni R, Colantonio S, Skrzypczyński P, Stefanowski J. Reproducibility of machine learning: Terminology, recommendations and open issues. *arXiv*. 2023 Feb 24. Available from: https://arxiv.org/abs/2302.12691

Beal J, Haddock-Angelli T, Farny NG, Rettberg R. Time to get serious about measurement in synthetic biology. *Trends Biotechnol*. 2018 Sep;36(9):869–71. doi:10.1016/j.tibtech.2018.05.003.

Brown L, Green CL, Jones N, Stewart JJ, Fraser S, Howell K, Xu Y, Hill CG, Wiwi CA, White WI, O'Brien PJ, Litwin V. Recommendations for the evaluation of specimen stability for flow cytometric testing during drug development. *J Immunol Methods*. 2015 Mar;418:1–8. doi:10.1016/j.jim.2015.01.008.

Kalina T. Reproducibility of flow cytometry through standardization: opportunities and challenges. *Cytometry A*. 2020 Feb;97(2):137–147. doi:10.1002/cyto.a.23901. Epub 2019 Oct 8. PMID:31593368.

Sommer U, Morales J, Groenewegen A, Müller A, Naab J, Woerly G, Kamphausen E, Marsot H, Bennett P, Kakkanaiah V, Vitaliti A. Implementation of highly sophisticated flow cytometry assays in multicenter clinical studies: considerations and guidance. *Bioanalysis*. 2015 Oct;7(10):1299–1311. doi:10.4155/bio.15.61. PMID:26045007.

Gianchecchi E, Torelli A, Piu P, Bonifazi C, Ganfini L, Montomoli E. Flow cytometry as an integrative method for the evaluation of vaccine immunogenicity: a validation approach. *Biochem Biophys Rep*. 2023 Apr 22;34:101472. doi:10.1016/j.bbrep.2023.101472. PMID: 37153861; PMCID: PMC10160688.

Newton HS, Zhang J, Donohue D, Unnithan R, Cedrone E, Xu J, Vermilya A, Malys T, Clogston JD, Dobrovolskaia MA. Multicolor flow cytometry-based immunophenotyping for preclinical characterization of nanotechnology-based formulations: an insight into structure–activity relationship and nanoparticle biocompatibility profiles. *Front Allergy*. 2023 Jul 4;4:1126012. doi:10.3389/falgy.2023.1126012. PMID:37470031; PMCID:PMC10353541.